Feb 17, 2022 / 09:20PM GMT
Daina Michelle Graybosch - SVB Leerink LLC, Research Division - MD of Immuno-Oncology & Senior Research Analyst
Hello, everyone. Welcome to our session this afternoon with Merck. I am really pleased to host Caroline Litchfield and Peter Dannenbaum.
And if you don't know me, I am the immuno-oncology analyst here at SVB Leerink. You may say, "Well, why do you cover Merck?" And it is because immuno-oncology is important to Merck. And actually, I love it because I love thinking about things other than immuno-oncology as well. And so always happy to talk with Merck management and really excited to have you both with us today.
Caroline Litchfield - Merck & Co., Inc. - Executive VP & CFO
Thank you, Daina.
Daina Michelle Graybosch - SVB Leerink LLC, Research Division - MD of Immuno-Oncology & Senior Research Analyst
And one point of process for people listening, if you'd like me to pose a question to Caroline or Peter, please look at the box below my finger, put it there. If you e-mail it to me, I
Merck & Co Inc at SVB Leerink Global Healthcare (Virtual) Transcript
Feb 18, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers